MIGLIACCIO, Anna Rita Franco,CHATURVEDI, Shalini,RADIMERSKI, Thomas,MENSSEN, Hans
申请号：
AU2019229885
公开号：
AU2019229885A1
申请日:
2019.03.07
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
The invention relates to the use of an anti-P-selectin antibody or binding fragment thereof, suitably crizanlizumab or a binding fragment thereof in the treatment of myelofibrosis (MF). The invention also relates to a pharmaceutical combination comprising a) an anti-P-Selectin antibody and b) at least one further therapeutic agent, preferably ruxolitinib or a 5 pharmaceutically acceptable salt thereof.
